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ee read with interest the article “Can We Account for Selec-
ion Bias? A Comparison of Bare Metal and Drug-Eluting Stents
n Belgium,” especially because the authors, together with a
eam of experts from the Belgian Health Care Knowledge Cen-
re (KCE), previously published a health technology assess-
ent (HTA) report and economic evaluation on this subject
sing the same data [1,2].
Both assessments are made for the Belgian population. The
wo studies, however, used a different methodological ap-
roach. The KCE analysis applied the “traditional” modeling
pproach to calculate the cost-effectiveness of drug-eluting
tents (DES) versus bare metal stents (BMS). The “alternative”
pproach used Ordinary Least Squares (OLS) and Instrumental
ariable (IV) methods to compare costs between DES and BMS
reatments.
It is fascinating to observe that using those two different
nalysis methods can lead to completely opposite conclu-
ions. The KCE report concluded that DES was not cost effec-
ive, due to the combination of a relatively high price for DES
nd the rather good results obtained with BMS. In contrast, the
conometric approach found no significant cost differences
or diabetic patients and cost savings with DES for the non-
iabetic population (if the cost for dual-antiplatelet therapy
as excluded).
Arguments both in favor and against different approaches
an be considered. It is not our aim to list these. The results of
he IV analysis, however, are intuitively hard to understand.
e illustrate this with “a back of the envelope” calculation (for
hich the exact calculations and details can be found in the
ull HTA report). In the real-world Belgian population, the cu-
ulative probability for a repeat percutaneous coronary inter-
ention (PCI) within 1 year was on average 15% in patients
ctually receiving a BMS (n 11,453). Less than 50% of these
e-interventions were due to restenosis (defined in the
tudy as a re-PCI in the same vessel as the initial interven-
ion). Based on randomized controlled trials it was assumed
hat approximately two-thirds of these re-interventions
ould be avoided if patients would receive a DES instead of
BMS. Consequently, this would result in an absolute treat-
ent effect of 5% fewer PCI re-interventions at the most.Funding: The authors have no financial relationships to disclose.ith a re-PCI cost of about €7000, the initial extra cost for
he health care payer of €1000 for a DES per patient is diffi-
ult to be outweighed. Furthermore, extra costs for anti-
latelet treatment have to be taken into account (which was
one in the KCE cost-effectiveness analysis). Even with an
ptimistic 100% treatment effect to avoid all restenosis, cost
avings would still not be reached with current DES charges
ue to the relatively good results with BMS. Translating the
arge relative treatment effect on a relatively small baseline
isk for re-interventions is translated in small absolute
ains, which eventually determine the intervention’s cost
ffectiveness.
So why do we observe this difference using two radically
ifferent research methods? In theory, the instrumental vari-
ble approach can measure the treatment effect using obser-
ational data and adjusting for observable and non-observ-
ble confounding factors. However, the practical use of this
pproach depends on the quality of the instrument, which
s difficult to assess. As the authors mentioned, it cannot be
uled out that the treatment effect model does not correct
or all observed or unobserved characteristics and that the
stimated treatment effect is biased, possibly due to weak
nstruments. The contrast with the traditional, but more
ransparent, approach confirms this and indicates that one
as to be careful using this approach to make policy recom-
endations.
This discussion demonstrates that clever techniques
hould be used carefully and special attention to bias
hould be monitored that would favor instruments leading
o “positive” findings. Nevertheless, we are also confident
hat econometric approaches using OLS, instrumental vari-
bles or other techniques could have their merits, e.g., to try
o estimate causal relationships when controlled experi-
ents are not feasible or to formulate hypotheses that need
urther research. It is necessary to investigate the validity
nd limitations of these approaches. However, with current
nowledge, cost-effectiveness calculations preferably use
ransparent techniques and should use data from well-per-
ormed RCTs (if available) to reflect the relative treatment
ffect.
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